Non-alcoholic fatty liver disease: A patient guideline

Sven M. Francque; Giulio Marchesini; Achim Kautz; Martine Walmsley; Rebecca Dorner; Jeffrey V. Lazarus; Shira Zelber-Sagi; Kate Hallsworth; Luca Busetto; Gema Frühbeck; Dror Dicker; Euan Woodward; Marko Korenjak; José Willemse; Gerardus H. Koek; Shlomo Vinker; Mehmet Ungan; Juan M. Mendive; Christos Lionis

doi:10.1016/j.jhepr.2021.100322

Non-alcoholic fatty liver disease: A patient guideline

Sven M. Francque^*, Giulio Marchesini, Achim Kautz, Martine Walmsley, Rebecca Dorner, Jeffrey V. Lazarus, Shira Zelber-Sagi, Kate Hallsworth, Luca Busetto, Gema Frühbeck, Dror Dicker, Euan Woodward, Marko Korenjak, José Willemse, Gerardus H. Koek, Shlomo Vinker, Mehmet Ungan, Juan M. Mendive, Christos Lionis

^*Corresponding author for this work

Family Medicine

Research output: Contribution to journal › Article › peer-review

168 Scopus citations

Abstract

This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions.

Original language	English
Article number	100322
Journal	JHEP Reports
Volume	3
Issue number	5
DOIs	https://doi.org/10.1016/j.jhepr.2021.100322
State	Published - Oct 2021

Funding

Funders	Funder number
Deutsche Leberhilfe
German Liver Help Association
Gilead Sciences
Global Liver Institute
Italian Liver Patients Association
European Coalition for People Living with Obesity
Ivan Gardini and Marco Bartoli
Meso Scale Diagnostics
UK Research and Innovation	106175

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jhepr.2021.100322

Cite this

Francque, S. M., Marchesini, G., Kautz, A., Walmsley, M., Dorner, R., Lazarus, J. V., Zelber-Sagi, S., Hallsworth, K., Busetto, L., Frühbeck, G., Dicker, D., Woodward, E., Korenjak, M., Willemse, J., Koek, G. H., Vinker, S., Ungan, M., Mendive, J. M., & Lionis, C. (2021). Non-alcoholic fatty liver disease: A patient guideline. JHEP Reports, 3(5), Article 100322. https://doi.org/10.1016/j.jhepr.2021.100322

@article{56ecf3a8f0e44654a981484e6476a7f9,

title = "Non-alcoholic fatty liver disease: A patient guideline",

abstract = "This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions.",

author = "Francque, {Sven M.} and Giulio Marchesini and Achim Kautz and Martine Walmsley and Rebecca Dorner and Lazarus, {Jeffrey V.} and Shira Zelber-Sagi and Kate Hallsworth and Luca Busetto and Gema Fr{\"u}hbeck and Dror Dicker and Euan Woodward and Marko Korenjak and Jos{\'e} Willemse and Koek, {Gerardus H.} and Shlomo Vinker and Mehmet Ungan and Mendive, {Juan M.} and Christos Lionis",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors",

year = "2021",

month = oct,

doi = "10.1016/j.jhepr.2021.100322",

language = "אנגלית",

volume = "3",

journal = "JHEP Reports",

issn = "2589-5559",

publisher = "Elsevier B.V.",

number = "5",

}

Francque, SM, Marchesini, G, Kautz, A, Walmsley, M, Dorner, R, Lazarus, JV, Zelber-Sagi, S, Hallsworth, K, Busetto, L, Frühbeck, G, Dicker, D, Woodward, E, Korenjak, M, Willemse, J, Koek, GH, Vinker, S, Ungan, M, Mendive, JM & Lionis, C 2021, 'Non-alcoholic fatty liver disease: A patient guideline', JHEP Reports, vol. 3, no. 5, 100322. https://doi.org/10.1016/j.jhepr.2021.100322

TY - JOUR

T1 - Non-alcoholic fatty liver disease

T2 - A patient guideline

AU - Francque, Sven M.

AU - Marchesini, Giulio

AU - Kautz, Achim

AU - Walmsley, Martine

AU - Dorner, Rebecca

AU - Lazarus, Jeffrey V.

AU - Zelber-Sagi, Shira

AU - Hallsworth, Kate

AU - Busetto, Luca

AU - Frühbeck, Gema

AU - Dicker, Dror

AU - Woodward, Euan

AU - Korenjak, Marko

AU - Willemse, José

AU - Koek, Gerardus H.

AU - Vinker, Shlomo

AU - Ungan, Mehmet

AU - Mendive, Juan M.

AU - Lionis, Christos

PY - 2021/10

Y1 - 2021/10

N2 - This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions.

AB - This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions.

UR - http://www.scopus.com/inward/record.url?scp=85126729646&partnerID=8YFLogxK

U2 - 10.1016/j.jhepr.2021.100322

DO - 10.1016/j.jhepr.2021.100322

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 34693236

AN - SCOPUS:85126729646

SN - 2589-5559

VL - 3

JO - JHEP Reports

JF - JHEP Reports

IS - 5

M1 - 100322

ER -

Non-alcoholic fatty liver disease: A patient guideline

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this